Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
IPSC Stock Chart & Stats
$1.08
<$0.01(0.47%)
At close: 4:00 PM EST
$1.08
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.34 - $1.27
Previous CloseN/A
Volume712.78K
Average Volume (3M)1.33M
Market Cap
$94.83M
Enterprise Value-$44.73M
Total Cash (Recent Filing)$132.75M
Total Debt (Recent Filing)$44.96M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding87,405,310
10 Day Avg. Volume1,954,645
30 Day Avg. Volume1,333,579
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.49
Price to Sales (P/S)12.06
P/FCF Ratio-0.72
Enterprise Value/Market Cap-0.47
Enterprise Value/Revenue-0.39
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda3.15
Forecast
1Y Price Target
$5.00Price Target Upside362.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost ManagementCost-cutting initiatives will extend the company's runway by an extra year to 4Q27.
Financial ResourcesThe company reported $158.5M in cash, cash equivalents, and investments, expected to fund operations into 4Q27.
Product DevelopmentCNTY-813 has been nominated as a new engineered iPSC-derived beta islet cell program with Allo-Evasion 5.0, currently in preclinical development for Type 1 diabetes.
Bears Say
Clinical TrialsEnrollment in the CALiPSO-1 trial is still lagging, with only two patients dosed as of 2Q.
Market PositionThe company has been downgraded to Market Perform from Outperform due to the de-prioritization of their sole clinical asset.
Strategic FocusThe decision to focus on more innovative preclinical programs leaves the company without value-inflecting clinical catalysts for approximately 12-15 months.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.34 and its highest was $1.26 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $94.83M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 72 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.062.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 87,405,310 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -17.857%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (362.96% Upside)
$5.00 (362.96% Upside)
Insider Transactions
Bought Shares
Worth $78.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.53%
12-Months-Change
Fundamentals
Return on Equity
-14.23%
Trailing 12-Months
Asset Growth
-37.03%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.00
▲(362.96% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
6.34% Insiders
2.60% Mutual Funds
10.48% Other Institutional Investors
78.49% Public Companies and
Individual Investors